


Roselipin


1. Discovery, producing organism and structure^{1,2)}

Roselipins were isolated from the culture broth of *Gliocladium roseum* strain KF-1040 and recognized to be inhibitors of diacylglycerol acyltransferase (DGAT). Four active compounds, designated roselipins 1A, 1B, 2A and 2B were isolated. Roselipins A and B are stereoisomers of D-arabinitol.



Gliocladium roseum KF-1040

Bar: 5 μm



2. Physical data (Roselipin 1A)²⁾

White power. C₄₀H₇₂O₁₄; mol wt 776.49. Sol. in MeOH, CHCl₃, CH₃CN, acetone, EtOH, EtOAc. Insol in. H₂O, hexane.

3. Biological activity^{1,3-7)}

1) DGAT inhibitory activity^{1,3,4)}

DGAT is involved in triacylglycerol formation. Therefore, DGAT is considered a new target for treating diseases caused by TG accumulation including; obesity, fatty liver and hypertriglyceridemia [See Amidepsine (p. 68)]. Roselipins inhibit DGAT activity in rat microsomes with similar IC₅₀ values.

Demansyl and/or dearabinitoyl roselipins were prepared chemically and enzymatically. Demansyl roselipins conserved DGAT inhibitory activity, while others lost activity, indicating that the arabinitoyl fatty acid core is essential for eliciting activity.

Compound	IC ₅₀ (μM)		
	Enzyme assay	Cell assay	
Roselipin	1A	17	39
	1B	15	32
	2A	22	24
	2B	18	18
Derivative	R-3A	60	11
	R-3B	33	10
	R-4	> 760	200
	R-5	> 960	250

Roselipins are selective inhibitors of DGAT2. Roselipins 1A, 1B, 2A, and 2B inhibited DGAT2 with IC₅₀ values of 30-50 μM, however showed almost no inhibition against DGAT1 even at 200 μM.⁵⁾

2) HIV integrase inhibitory activity⁶⁾

Roselipins 2A and 2B mixture showed HIV integrase inhibitory activity with IC₅₀ of 8.5 μM.

3) Inhibitory activity of chemokine receptor CXCR3 interaction⁷⁾

Roselipins blocked chemokine receptor CXCR3 interaction of IP-10 ligand. Roselipins 2A, 2B and 1A showed IC₅₀ values of 14.6, 23.5, and 41 μM, respectively.

4. References

- [724] H. Tomoda *et al.*, *J. Antibiot.* **52**, 689-694 (1999)
- [727] N. Tabata *et al.*, *J. Antibiot.* **52**, 815-826 (1999)
- [786] H. Tomoda and S. Ōmura, In *Enzyme Technology for Pharmaceutical and Biotechnological Applications*. (Eds Kirst, H., Yeh, W.-K. & Zmijewski, M.) pp.343-378, Marcel Dekker, Inc., New York. (2001)
- [822] H. Tomoda *et al.*, *J. Antibiot.* **56**, 24-29 (2003)
- [1030] J. Inokoshi *et al.*, *J. Antibiot.* **62**, 51-54 (2009)
- S. B. Singh *et al.*, *J. Ind. Microbiol. Biotechnol.* **30**, 721-731 (2003)
- J. G. Ondeyka *et al.*, *Mol. Diversity* **9**, 123-129 (2005)